AGENDA
Translational Advances in Cancer Prevention Agent Development
Sponsored by the Division of Cancer Prevention, National Cancer Institute
and the Office of Disease Prevention
DATE: August 27-28, 2020

Day 1 Morning Session (9:00 to 11:30 AM)

9:00-9:30 AM Welcome Remarks
Philip Castle, Ph.D., M.P.H., Director, Division of Cancer Prevention, NCI
Mark Miller, Ph.D., Program Director, Division of Cancer Prevention, NCI

Session I* Advances in Small Molecule Agent Development
Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.

9:30-10:00 AM Speaker 1: Margie Clapper, Ph.D., Fox Chase Cancer Center
Estrogen metabolism: A target for intervention in non-small cell lung cancer

10:00-10:30 AM Speaker 2: Karen Liby, Ph.D., Michigan State University
Targeting the immune system for the prevention of Kras-driven cancers

10:30-11:00 AM Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio
Cancer and aging prevention by mTOR inhibition

11:00-11:30 AM Speaker 4: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center
Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters

11:30-12:15 PM Break

Day 1 Early Afternoon Session (12:15 to 3:15 PM)

12:15-1:15 AM Translational Research Plenary Speaker
Raymond DuBois, M.D., Ph.D., Medical University of South Carolina
Inflammation and inflammatory mediators as targets for cancer prevention/interception

*Session talks will be 20 min with 10 min Q&A
**Session II**

**Advances in Immunomodulatory Agent Development**

*Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.*

1:15-1:45 PM  
Speaker 1: Jill Siegfried, Ph.D., University of Minnesota  
*A STAT3 decoy for lung cancer prevention*

1:45-2:15 PM  
Speaker 2: Robert Glynn, Sc.D., Harvard Medical School  
*Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial*

2:15-2:45 PM  
Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia  
*CD137 immune checkpoint pathway as an effective target for cancer immunoprevention*

2:45-3:15 PM  
Speaker 4: Shadmehr Dehnehri, M.D., Ph.D., Massachusetts General Hospital  
*Epithelium-derived alarmins role in breast cancer immunoprevention*

3:15 – 4:00 PM  
**Break**

---

**Day 1 Late Afternoon Session (4:00 to 6:30 PM)**

**Session III**

**Alternative Dosing and Combination Strategies to Reduce Toxicity**

*Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.*

4:00-4:30 PM  
Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center  
*Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer*

4:30- 5:00 PM  
Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University  
*Location, location, location: oral cancer chemoprevention by local delivery*

5:00-5:30 PM  
Speaker 3: C.V. Rao, Ph.D., University of Oklahoma  
*Safer chemopreventive approaches to colonic adenoma prevention*

5:30-6:00 PM  
Speaker 4: Emmanuelle Meuillet, Ph.D., PHusis Therapeutics  
*Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427*

6:00-6:30 PM  
Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center  
*Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP*
Day 2 Morning Session (10:00 AM to 1:30 PM)

10:00-10:15 AM  Open Morning Session
Altaf Mohammed, Ph.D., Division of Cancer Prevention, NCI

10:15-11:00 AM  NCI PREVENT Preclinical Drug Development Program
Mark Miller, Ph.D., Division of Cancer Prevention, NCI

Session IV
Emerging Vaccines for Cancer Prevention
Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.

11:00-11:30 AM  Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University
Immunoprevention for Lynch Syndrome

11:30-12:00 PM  Speaker 2: Robert Schoen, M.D., M.P.H., University of Pittsburgh
MUC1 vaccine for prevention of colorectal adenoma

12:00-12:30 PM  Speaker 3: Richard Roden, Ph.D., Johns Hopkins University
Development of vaccines for broad protection against and elimination of HPV infection

12:30-1:00 PM  Speaker 4: Bryon Johnson, Ph.D., Wisconsin Medical Center
Development of a Kras preventive vaccine

1:00-1:30 PM  Speaker 5: Mary (Nora) Disis, M.D., University of Washington
Vaccines targeting cancer initiation associated proteins

1:30 -2:30 PM  Break

Day 2 Afternoon Session (2:30 to 6:15 PM)

2:30-3:30 PM  Clinical Research Plenary Speaker
Powel Brown, M.D., Ph.D., MD Anderson Cancer Center
Novel cancer prevention strategies in the molecular era

Session V
Cancer Prevention Clinical Trials
Co-Chairs: Peter Allen, M.D. and Eva Szabo, M.D.

3:30-4:00 PM  Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)
Eva Szabo, M.D., Division of Cancer Prevention, NCI
4:00-4:30 PM  Speaker 1: Peter Allen, M.D., Duke University

*Intraductal Papillary Mucinous neoplasms of the pancreas: An opportunity to prevent pancreatic cancer?*

4:30-5:00 PM  Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center

*Cancer immune-interception for Lynch Syndrome*

5:00-5:30 PM  Speaker 3: Seema Khan, M.D., Northwestern University

*Local transdermal drug delivery to the breast for cancer prevention*

5:30-6:00 PM  Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital

*Novel strategies for aspirin prevention of cancer*

6:00-6:15 PM  **Closing Remarks, Future Plans for Prevention Meetings**

Altaf Mohammed, Ph.D., Division of Cancer Prevention, NCI
Mark Miller, Ph.D., Division of Cancer Prevention, NCI